Pfizer (NYSE:PFE) reported positive topline Phase 3 results from its BREAKWATER oncology trial in metastatic colorectal ...
Pfizer's long-acting GLP-1 weight loss candidate could set the stage for a stock rally.
Pfizer (NYSE:PFE) is set to report its second quarter earnings on Tuesday, August 5th, before the market opens, with analysts projecting a modest performance rebound. The consensus EPS estimate stands ...
Pfizer (NYSE:PFE) is stepping deeper into the global weight loss race, striking a deal with Hangzhou Sciwind Bioscience for exclusive commercialization rights to ecnoglutide in mainland China, in an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results